Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 … – Markets Insider
|
Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 …
Markets Insider 25, 2017 /PRNewswire/ — Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced that the first patient received treatment in the Phase 1/2 clinical trial ("the Alta trial") evaluating SB-525, an investigational gene … |
